Derivatisation of biological molecules
AssigneeBiocompatibles UK Limited
InventorsStephen James Brocchini, Antony Robert Godwin, Yiqing Tang, Andrew Lennard Lewis
Life of this patent
Estimating the term…
Loading patent…
AssigneeBiocompatibles UK Limited
InventorsStephen James Brocchini, Antony Robert Godwin, Yiqing Tang, Andrew Lennard Lewis
Estimating the term…
The present disclosure relates to a new polymerization process in which ethylenically unsaturated monomers are polymerised by a living radical polymerization process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-α.
A compound of general formula I
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Cytokines; Lymphokines; Interferons: interferons [IFN]
The modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule: obtained by reactions only…
Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes: the organic…
Drugs for immunological or allergic disorders
About 2 years 4 months of term left · ends 26 Feb 2029 (estimated)
The present invention relates to the modification of biological molecules for the purpose of improving their efficacy as therapeutic treatments.
Traditionally, therapeutic proteins have several inherent shortcomings. Proteins often have short half-lives, wide tissue distribution, the potential for immunogenicity, and sometimes need to be dosed frequently. When frequent dosing is required, it can result in increased cost, toxicity and complicated dosing regimens. In an effort to overcome these shortcomings, researchers have looked at improving the delivery systems of proteins. Among the potential solutions lies PEGylation, the attachment of a flexible strand or strands of polyethylene glycol (PEG) to a protein.
When attached to a drug or protein, PEG polymer chains can sustain bioavailability by protecting the drug molecules from immune responses and other clearance mechanisms. PEGylation has been shown to favourably alter pharmacokinetics by prolonging circulation time and decreasing clearance rates, to delay absorption, decrease systemic toxicity and to display increased clinical efficacy (partly by exhibiting reduced proteolysis).
The invention will now be illustrated by the following Examples, which refer to FIGS. 1-14, in which
FIG. 1 shows the mechanism of PC-polymer insertion into a protein disulfide bridge;
FIG. 2 shows the 1H NMR spectrum of initiator (4);
In this invention, such polymers, based upon phosphorylcholine (PC) are functionalised with an end-terminal linking group capable of insertion into the disulfide bridges or reaction with terminal cysteine residues of many commonly used therapeutic proteins. FIG. 1 shows the mechanism of PC polymer insertion.
This invention provides for a method of attaching novel PC polymers, useful for modification of proteins by virtue of their biocompatible properties, much akin to the PEG counterparts. The polymer is moreover, selectively attached at specific positions within the protein structure dictated by the position of the disulfide bridges or terminal cysteine residues in the conformational tertiary structure of the protein.
The benzoic acid derivative of the bis-sulfide was prepared as described by Liberatore, F., Eberle, M. & Lawton, R. G. Bioconjug. Chem. 1, 36-50 (1990).